Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma By Ogkologos - March 16, 2026 248 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Does Eating Processed Meat Increase Your Risk for Cancer? September 19, 2023 Παρακολούθηση και Φροντίδα January 14, 2019 FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or... July 12, 2021 Mom Who Lost Child Donates Breast Milk To Mom With Cancer February 27, 2019 Load more HOT NEWS Breaking the silence: when cancer steals your voice Conducting Phase I Clinical Trials During the COVID-19 Pandemic Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate... New on NCI’s Websites for December 2022
